# Debate prop_0628__grok-4.5-high__muse-spark-1.1-high__s0__tpl_placement_active_20260320f

- topic_id: prop_0628
- proposition: Governments should require frontier AI model developers to complete and publish standardized pre-deployment safety evaluations, with penalties for noncompliance.
- model_pro: grok-4.5-high
- model_con: muse-spark-1.1-high
- side_swap: False

## Turn 1: PRO Opening

- model: grok-4.5-high
- raw_words: 247
- clipped_words: 247
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] Governments must require frontier AI developers to complete and publish standardized pre-deployment safety evaluations, backed by penalties. These systems already draft phishing tools, assist biological planning, and scale persuasion content. Releasing them first and testing later is how avoidable harm hardens into permanent exposure.
[P1.2] Standardized evaluations close gaps voluntary testing leaves open. They require every major lab to measure the same high-stakes categories—cyber-offensive potential, biotech misuse, and deceptive behavior—on a shared scale so results can be compared rather than spun. Publication puts those findings in front of governments, researchers, and the public, ending the asymmetry in which one lab can bury what another has already measured. Penalties turn safety from optional branding into a binding cost of entry.
[P1.3] Without them, the commercial pressure is always to ship, claim internal diligence, and let externalities fall elsewhere.
[P1.4] We already impose this logic on high-risk technologies. Drug makers cannot market a compound until standardized trials are finished and data disclosed. Automakers face crash-test rules. Aviation does not let carriers invent private airworthiness criteria.
[P1.5] Frontier models now sit in the same risk class: tools that can accelerate research, automate attacks, or shape public belief at population scale. Treating them as ordinary consumer software is not restraint; it is abdication.
[P1.6] The alternative is a release race that rewards whoever tests least. Mandatory public evaluations raise the floor without banning progress. They make reckless deployment expensive instead of profitable, and they give society a chance to act before the consequences are already irreversible.

## Turn 2: CON Opening

- model: muse-spark-1.1-high
- raw_words: 302
- clipped_words: 302
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7], [C1.8]
- cited_claim_ids: [P1.2], [P1.1], [P1.4], [P1.6]
- missing_claim_id_refs: (none)

[C1.1] Mandating that frontier labs complete and publish standardized safety evaluations before deployment fails on its own terms: it makes society less safe.
[C1.2] Publication is the core flaw. Requiring public disclosure of how well a model performs at [P1.2] cyber-offensive operations, biotech misuse, and deception does not neutralize those dangers. It advertises them. A public scoreboard that says Model X scores high on bioweapon enablement or automated hacking is a shopping catalog for malicious actors, rival militaries, and criminals.
[C1.3] Drugs publish safety data after risks are mitigated, not a detailed map of how to cause harm [P1.1]. This proposal does the opposite.
[C1.4] Standardization is the second flaw. The analogy to crash tests and clinical trials [P1.4] collapses because frontier models are general purpose and adversarial. A crash test measures one physics outcome. "Deceptive behavior" has no stable metric.
[C1.5] A fixed government test will freeze last year's threat model, incentivize teaching to the test, and reward labs that can game a checkbox. It creates a false certification of safety while diverting effort from the open-ended red-teaming that actually finds novel failures. That does not raise the floor [P1.6]; it puts a flimsy floor over a deeper hole.
[C1.6] Then add penalties and you entrench incumbents and export risk. Only a handful of corporations can afford months of compliance review and legal exposure. Academic labs and open-source teams cannot. Development does not stop; it moves to jurisdictions with no such publication rule, less visible and less accountable.
[C1.7] You also force disclosure of trade secrets and evaluation methods that competitors -- including state actors -- can then copy for free.
[C1.8] If assurance is needed, require confidential audits to a regulator under strict controls, not a mandatory public dossier of dangerous capabilities. As written, with publication and penalties, this policy weaponizes safety information, ossifies testing, and centralizes power.

## Turn 3: PRO Rebuttal 1

- model: grok-4.5-high
- raw_words: 312
- clipped_words: 312
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5]
- cited_claim_ids: [C1.2], [C1.3], [C1.8]
- missing_claim_id_refs: (none)

[P2.1] Publication does not make society less safe; silence does. CON claims a public scoreboard becomes a “shopping catalog” for cyber and biotech misuse [C1.2]. That confuses evaluation results with exploit manuals. Reporting that a model crosses a fixed threshold on known biotech-planning tasks or automated phishing generation advertises capability presence, not step-by-step recipes.
[P2.2] Malicious actors already probe these systems via APIs, leaks, and reverse engineering; what they lack is early, comparable warning that lets defenders and governments prioritize before mass release. Drug regulators publish adverse-event rates and contraindications after trials precisely so society can respond; they do not wait for “mitigation complete” to hide risks [C1.3]. Withholding frontier scores simply preserves the lab’s information monopoly while the model ships.
[P2.3] The standardization attack also fails on its own terms. CON says general-purpose, adversarial systems cannot share metrics and that fixed tests freeze last year’s threat model [C1.4–C1.5]. Crash tests and clinical endpoints already handle complex, evolving risks with periodic updates; the same mechanism works here. Shared categories for cyber-offensive potential, biotech enablement, and deception give outsiders a common language instead of each lab’s self-serving dashboard.
[P2.4] Teaching to the test is a second-order problem that still leaves residual risk lower than no baseline at all. Confidential regulator-only audits [C1.8] restore the exact asymmetry PRO targets: one firm can bury what another has already measured, and the public never sees the comparison.
[P2.5] Penalties and compliance costs do not “export risk” into unaccountable jurisdictions so much as they stop domestic free-riding. Labs that already treat safety as optional branding will keep racing until the cost of noncompliance exceeds the profit of early release. Open and academic efforts can be scoped or exempted without gutting the rule for the systems that actually reach planetary scale. The motion as written raises the floor on high-stakes models before their externalities harden; CON’s alternative leaves those externalities optional and private.

## Turn 4: CON Rebuttal 1

- model: muse-spark-1.1-high
- raw_words: 299
- clipped_words: 299
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7]
- cited_claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5]
- missing_claim_id_refs: (none)

[C2.1] PRO says publishing a score isn't a manual [P2.1]. That distinction collapses in practice. Telling the world a model "exceeds threshold on bioweapon planning" is not abstract — it's a verified shopping recommendation for anyone hunting that capability. Hackers don't need recipes if you certify which assistant already works.
[C2.2] The fact adversaries probe APIs today [P2.2] makes this worse, not better; a government seal of "yes, this works for automated phishing" removes the uncertainty that currently deters low-skill actors.
[C2.3] Defenders don't need that press release. Early warning can go to CISA, HHS and other regulators under NDA the next day. Public disclosure adds zero defensive speed but gives offense global distribution. Drug labels [P2.2] prove the point: they publish contraindications to help patients avoid harm after a drug is proven safe, not a leaderboard of which compound is best at causing clots.
[C2.4] The standardization defense [P2.3] ignores adversarial dynamics. Crash dummies don't learn to duck the test. Models do. When deception has no stable metric, a fixed government checklist becomes Goodhart's law on stilts: labs optimize for the benchmark, deploy a model that passes, and the public gets a false certification of safety.
[C2.5] [P2.4] calls gaming the test second-order. In security, gaming the test is the whole game. That is worse than no floor — it is a painted floor over a sinkhole.
[C2.6] And the compliance fix [P2.5] is incoherent. If you exempt open and academic builds, you exempt the models most likely to proliferate unmonitored. If you don't, you hand the frontier to two U.S. giants who can afford compliance theater and lawyers. Either way, work migrates offshore, where neither publication nor penalty reaches.
[C2.7] PRO wants to end asymmetry. Its publication rule creates a deadlier symmetry: attackers and defenders learn at once, but attackers need only one success.

## Turn 5: PRO Pressure Questions

- model: grok-4.5-high
- raw_words: 71
- clipped_words: 71
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C2.2], [C1.8]
- missing_claim_id_refs: (none)

[P3.1] Q1: Since adversaries already probe APIs and reverse-engineer models today [C2.2], what concrete mechanism turns a public threshold score into a worse "shopping recommendation" than the status quo of secret self-reports that leave defenders and governments flying blind?
[P3.2] Q2: If confidential regulator-only audits [C1.8] are the alternative, how do they end the lab information monopoly and commercial race to ship when comparative results stay private and noncompliance carries no public penalty?

## Turn 6: CON Pressure Questions

- model: muse-spark-1.1-high
- raw_words: 67
- clipped_words: 67
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: [P2.1], [P1.2], [P2.3]
- missing_claim_id_refs: (none)

[C3.1] Q1: If publishing a threshold score isn't a manual [P2.1], what will publication actually contain that lets outsiders compare models [P1.2] without certifying which model is best at bioweapons or hacking and how it was elicited?
[C3.2] Q2: Who maintains the "standardized" tests and how do you update them fast enough to stop teaching-to-the-test [P2.3] while still providing legal certainty for penalties, rather than a stale, gameable certification?

## Turn 7: PRO Rebuttal 2

- model: grok-4.5-high
- raw_words: 263
- clipped_words: 263
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P4.1] A1: Publication contains pass/fail or graded results on shared, high-level proxies—threshold crossings for biotech-planning success rates, phishing-generation reliability, or deception indicators—using abstract scales, not full prompts, toolchains, or elicitation scripts. Outsiders compare residual risk across labs without receiving a usable attack recipe or "best at" shopping list.
[P4.2] A2: An independent standards body under government mandate (analogous to existing technical agencies) owns versioned test suites, updating them on fixed cycles plus emergency amendments when novel threats appear. Legal certainty comes from published version numbers and safe-harbor windows; labs are scored against the active suite, not a frozen forever checklist, so penalties attach only after notice and update lag.
[P4.3] These answers close CON’s claimed dilemmas without surrendering the motion. Threshold scores strip away the lab monopoly that now lets one firm bury results another has already seen; defenders and agencies receive comparable data before planetary release, while adversaries still face the same reverse-engineering cost they bear today. Versioned public standards under an accountable steward block permanent teaching-to-the-test more effectively than private lab dashboards or purely confidential audits, which CON itself admits leave comparative results hidden and free-riding unpunished. The commercial race continues only if noncompliance remains cheaper than early shipping; penalties reverse that calculus for the systems that actually scale.
[P4.4] Confidential-only pathways restore the exact asymmetry we set out to end—silent self-reports and optional branding—while publication of high-level results gives society the shared floor without handing out exploit manuals. On balance, mandatory standardized disclosure plus enforcement still raises the safety floor before irreversible externalities lock in; the alternative leaves those externalities optional, private, and uncompared.

## Turn 8: CON Rebuttal 2

- model: muse-spark-1.1-high
- raw_words: 294
- clipped_words: 294
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5]
- cited_claim_ids: [P4.1], [C1.8], [P1.2], [P2.1], [P4.2]
- missing_claim_id_refs: (none)

[C4.1] A1: The mechanism is certified search-cost collapse. Under secrecy a low-tier actor must test ten models, pay for access, risk detection, and interpret noisy outputs with no idea which actually enables biotech uplift. A public graded score [P4.1] does that work for him: government-verified proof that Model X crosses the biotech-planning threshold and Model Y does not. That endorsement removes uncertainty, concentrates jailbreak effort and theft on one target, and tells attackers what is worth weaponizing.
[C4.2] Uncertainty deters; publication subsidizes.
[C4.3] A2: Confidential regulator audits [C1.8] break the monopoly because the regulator, unlike any single lab, sees across all frontier labs. It can block or condition release, circulate sanitized TTPs to CISA/HHS under NDA, and publicly penalize failure to file or shipping in defiance of a hold. The race stops because penalty attaches to skipping the audit itself. You get deterrence from a public "noncompliant / held" notice without publishing a leaderboard of who is best at bioweapons.
[C4.4] Your own answers prove the trade-off is fatal to PRO. [P4.1] says publication will be pass/fail or graded proxies so outsiders can compare [P1.2]. Any grade that makes comparison meaningful necessarily certifies which model is most weapons-capable - that is exactly the shopping recommendation you denied in [P2.1]. You cannot have comparability without advertisement.
[C4.5] And [P4.2] shows standardization cannot satisfy legality and agility at once. A versioned body with emergency amendments either updates fast and destroys legal certainty for penalties, or grants safe-harbor months where a dangerous model ships legally while the test is stale. Labs then teach to the known suite, collect a government seal of safety, and the public gets false assurance. That painted floor plus a public catalog helps offense more than defense, because attackers need one success where defenders must prevent every one.

## Turn 9: PRO Closing

- model: grok-4.5-high
- raw_words: 167
- clipped_words: 167
- claim_ids: [P5.1], [P5.2], [P5.3]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P5.1] Only mandatory standardized public evaluations, backed by penalties, can force a shared safety floor before frontier models ship at planetary scale. That is the decisive reason this side wins. CON’s preferred confidential audits leave comparative residual risk locked away: the regulator may see across labs, yet the public and independent researchers do not. Free-riding continues, and society learns of threshold-crossing cyber or biotech capabilities only after release has already locked them into the ecosystem.
[P5.2] Publication of high-level pass/fail or graded proxies on fixed categories closes the monopoly without handing out manuals—adversaries already reverse-engineer, but defenders gain the early comparable signal they now lack. The commercial incentive always rewards whoever tests least under secrecy; attaching penalties to published standardized results reverses that calculus for the systems that actually matter. Confidential pathways merely rename the optional branding we started with. Society cannot act on harms it is systematically prevented from seeing and ranking.
[P5.3] The motion ends that blindness; the alternative does not. That is why governments should require it.

## Turn 10: CON Closing

- model: muse-spark-1.1-high
- raw_words: 167
- clipped_words: 167
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4]
- cited_claim_ids: [P1.2], [P4.1], [C4.1], [C2.7]
- missing_claim_id_refs: (none)

[C5.1] The proposition dies on its own definition of success. PRO wants publication so outsiders can compare residual risk [P1.2] using graded proxies [P4.1]. The decisive CON win is that meaningful comparison is inseparable from advertisement.
[C5.2] If the score is detailed enough to let a researcher, journalist, or regulator rank Model X above Y on bioweapon planning or phishing, it is by definition a government-certified answer to the question every low-skill threat actor is asking: which model actually works and is worth stealing, jailbreaking, and weaponizing. Uncertainty currently taxes attackers; [C4.1] shows publication pays that tax for them.
[C5.3] Defenders get nothing extra from that public leaderboard that a regulator with cross-lab view and a public "noncompliant / held" notice cannot provide faster and more quietly. PRO's symmetry — everyone learns at once — fails because [C2.7] attackers need one success while defenders must prevent every one.
[C5.4] You cannot have comparability without a shopping list. Because PRO needs comparability, it mandates the shopping list. That makes us less safe.
